Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Domitroban. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 7/20 | 0.96 |
| ▸ | PTGDR | Q13258 | 18/20 | 0.85 |
| ▸ | PTGIR | P43119 | 3/20 | 0.85 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Domitroban SCHEMBL710021 | 1.00 | TBXA2R (0.96) | TBXA2RPTGDRPTGIRTBXAS1 | |
| Domitroban SCHEMBL7600957 | 0.99 | TBXA2R (0.98) | TBXA2RPTGDRPTGIRTBXAS1 | |
| Domitroban SCHEMBL7600952 | 0.99 | TBXA2R (0.98) | TBXA2RPTGDRPTGIRTBXAS1 | |
| Domitroban SCHEMBL27571942 | 0.99 | TBXA2R (0.98) | TBXA2RPTGDRPTGIRTBXAS1 | |
| Domitroban SCHEMBL8539382 | 0.99 | TBXA2R (0.98) | TBXA2RPTGDRPTGIRTBXAS1 | |
| Domitroban SCHEMBL98346 | 0.99 | TBXA2R (0.98) | TBXA2RPTGDRPTGIRTBXAS1 | |
| Domitroban SCHEMBL7600963 | 0.99 | TBXA2R (0.98) | TBXA2RPTGDRPTGIRTBXAS1 | |
| Domitroban SCHEMBL98345 | 0.99 | TBXA2R (0.98) | TBXA2RPTGDRPTGIRTBXAS1 | |
| Domitroban SCHEMBL8539385 | 0.99 | TBXA2R (0.98) | TBXA2RPTGDRPTGIRTBXAS1 | |
| Domitroban SCHEMBL2232264 | 0.98 | TBXA2R (1.00) | TBXA2RPTGDRPTGIRTBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 246 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6436997-B1 | Endogenous nitric oxide synthesis under conditions of low oxygen tension | NITROMED, INC. | 2002-08-20 | — | — | US | claimed |
| US-12629379-B2 | Pharmaceutical composition for preventing, suppressing, or treating symptom associated with allergic reaction | NIPPON CHEMIPHAR CO., LTD. (JP) | 2026-05-19 | — | — | US | disclosed |
| US-20260000678-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOM ASSOCIATED WITH PSEUDO-ALLERGIC REACTION | TAKASAKI UNIV OF HEALTH AND WELFARE (JP) | 2026-01-01 | — | — | US | disclosed |
| US-20250197401-A1 | PURINONE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2025-06-19 | — | — | US | disclosed |
| US-12233071-B2 | Medicament for treating cough | NIPPON CHEMIPHAR CO., LTD. (JP) | 2025-02-25 | — | — | US | disclosed |
| EP-4501357-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR SUPPRESSING OR TREATING SYMPTOMS ACCOMPANYING PSEUDO-ALLERGIC REACTIONS | Takasaki University of Health and Welfare (JP) | 2025-02-05 | — | — | EP | disclosed |
| US-20240317751-A1 | PURINONE DERIVATIVE HYDROCHLORIDE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2024-09-26 | — | — | US | disclosed |
| US-20240083899-A1 | PURINONE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2024-03-14 | — | — | US | disclosed |
| US-11897885-B2 | Purinone derivative hydrochloride | ONO PHARMACEUTICAL CO., LTD. (JP) | 2024-02-13 | — | — | US | disclosed |
| WO-2023190826-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR SUPPRESSING OR TREATING SYMPTOMS ACCOMPANYING PSEUDO-ALLERGIC REACTIONS | 学校法人 高崎健康福祉大学 | 2023-10-05 | — | — | WO | disclosed |
| US-20050004097-A1 | Indole derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
| EP-1486491-A1 | CARBOXYOIC ACID COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-12-15 | — | — | EP | disclosed |
| US-20040242455-A1 | 5-amidino-n-(2-aminophenethyl)-n-hydroxy-benzenesulffonamide derivative, medical composition containing the same, pharmaceutical use thereof and intermediate therefor | KISSEI PAHRMACEUTICAL CO., LTD. (JP) | 2004-12-02 | — | — | US | disclosed |
| EP-1481969-A1 | PIPERIDINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-12-01 | — | — | EP | disclosed |
| EP-1447401-A1 | PIPERIDIN-2-ONE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-08-18 | — | — | EP | disclosed |
| EP-1443041-A1 | 5-AMIDINO-2-HYDROXYBENZENESULFONAMIDE DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE SAME, MEDICINAL USE THEREOF AND INTERMEDIATES IN THE PRODUCTION THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2004-08-04 | — | — | EP | disclosed |
| EP-1424335-A1 | INDOLE DERIVATIVES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-06-02 | — | — | EP | disclosed |
| EP-1424325-A1 | INDOLE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-06-02 | — | — | EP | disclosed |
| EP-1415983-A1 | 5-AMIDINO-N-(2-AMINOPHENETHYL)-HYDROXYBENZENESULFONAMIDE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND INTERMEDIATE THEREFOR | Kissei Pharmaceutical Co., Ltd. (JP) | 2004-05-06 | — | — | EP | disclosed |
| US-6436997-B1 | Endogenous nitric oxide synthesis under conditions of low oxygen tension | NITROMED, INC. | 2002-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12233071-B2 | Medicament for treating cough | P2RX4, P2RX3, P2RX5 | TBXA2R 172/4885PTGDR 659/4885PTGIR 404/4885 |
| US-20050004097-A1 | Indole derivatives | IDO1, IDO2, PTGIR | TBXA2R 30/4885PTGDR 6/4885PTGIR 3/4885 |
| US-20240317751-A1 | PURINONE DERIVATIVE HYDROCHLORIDE | BTK, P2RY1, P2RY13 | TBXA2R 1199/4885PTGDR 1041/4885PTGIR 719/4885 |
| US-11897885-B2 | Purinone derivative hydrochloride | BTK, P2RY1, P2RY13 | TBXA2R 1199/4885PTGDR 1041/4885PTGIR 719/4885 |
| US-12629379-B2 | Pharmaceutical composition for preventing, suppressing, or treating symptom associated with allergic reaction | HRH2, HRH4, HRH1 | TBXA2R 37/4885PTGDR 239/4885PTGIR 175/4885 |
| US-20260000678-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOM ASSOCIATED WITH PSEUDO-ALLERGIC REACTION | TRPV1, TRPV4, TRPV5 | TBXA2R 337/4885PTGDR 232/4885PTGIR 84/4885 |
| US-20250197401-A1 | PURINONE DERIVATIVE | BTK, KIT, SYK | TBXA2R 1494/4885PTGDR 788/4885PTGIR 1424/4885 |
| US-20240083899-A1 | PURINONE DERIVATIVE | BTK, KIT, SYK | TBXA2R 1494/4885PTGDR 788/4885PTGIR 1424/4885 |
| US-20040242455-A1 | 5-amidino-n-(2-aminophenethyl)-n-hydroxy-benzenesulffonamide derivative, medical composition containing the same, pharmaceutical use thereof and intermediate therefor | F11, F2, F7 | TBXA2R 66/4885PTGDR 827/4885PTGIR 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.